Trial Profile
A 16-week Randomized, Open-label, Multicenter Study to Assess the Superiority of Secukinumab Over Guselkumab in the Complete Treatment of Ustekinumab Resistant Psoriatic Plaques
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Guselkumab
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Acronyms ARROW
- Sponsors Novartis Pharmaceuticals
- 01 Oct 2023 Results assessing clinical and molecular effects of direct IL-17A (with secukinumab) versus selective IL-23 inhibition (with guselkumab) in patients with anti-IL-12/23 (ustekinumab)-refractory psoriatic plaques published in the Experimental Dermatology
- 16 Jul 2020 Status changed from active, no longer recruiting to completed.
- 25 Mar 2020 This trial has been completed in Germany according to European Clinical Trials Database record.